Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571711 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ENPP2PTGER4GRM2PSEN1 | |
| SCHEMBL6571724 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ENPP2PTGER4GRM2PSEN1 | |
| SCHEMBL6571716 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ENPP2PTGER4GRM2PSEN1 | |
| SCHEMBL6571719 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ENPP2PTGER4GRM2PSEN1 | |
| SCHEMBL6574963 | 0.91 | PTGER4 (0.39) | L3MBTL1PTGER4GRM2PSEN1PSEN2 | |
| SCHEMBL6574955 | 0.91 | PTGER4 (0.39) | L3MBTL1PTGER4GRM2PSEN1PSEN2 | |
| SCHEMBL6574950 | 0.91 | PTGER4 (0.39) | L3MBTL1PTGER4GRM2PSEN1PSEN2 | |
| SCHEMBL6574958 | 0.91 | PTGER4 (0.39) | L3MBTL1PTGER4GRM2PSEN1PSEN2 | |
| SCHEMBL6574951 | 0.91 | PTGER4 (0.39) | L3MBTL1PTGER4GRM2PSEN1PSEN2 | |
| SCHEMBL6572658 | 0.87 | PTGER4 (0.35) | L3MBTL1PTGER4GRM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | CAMERON KIMBERLY O (US) | 2003-01-09 | — | — | US | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| WO-1998058911-A2 | PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-12-30 | — | — | WO | claimed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | disclosed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6531485-B2 | For therapy of bone disorders including osteoporosis | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | CAMERON KIMBERLY O (US) | 2003-01-09 | — | — | US | disclosed |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | CAMERON KIMBERLY O (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1121939-A2 | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | PTGER1, PTGER4, PTGIR | L3MBTL1 4609/4885ENPP2 30/4885PTGER4 2/4885 |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | PTGER2, PTGER1, PTGER4 | L3MBTL1 2928/4885ENPP2 17/4885PTGER4 3/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | L3MBTL1 3968/4885ENPP2 43/4885PTGER4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.